Therapeutic drug monitoring in anti-tuberculosis treatment: A systematic review and meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 6, 2016, Pages 819-826

  Mota, L ^a   Al Efraij, K ^b   Campbell, J R ^b   Cook, V J ^a,b   Marra, F ^b   Johnston, J ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Metaanalysis; TB; Therapeutic drug monitoring

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; COMORBIDITY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; DOSE RESPONSE; FACTUAL DATABASE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTITUBERCULAR AGENTS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ETHAMBUTOL; HUMANS; ISONIAZID; PYRAZINAMIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84966656965     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0803     Document Type: Article

References (61)

1. World Health Organization Global tuberculosis report, 2013 WHO/HTM/TB/2013.11 Geneva, Switzerland: WHO, 2013.
2. World Health Organization Treatment of tuberculosis: guidelines WHO/HTM/TB/2009.420 Geneva, Switzerland: WHO, 2010.
3. Menzies D, Benedetti A, Paydar A, et al Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-Analysis PLOS Med 2009; 6: e1000146.
4. Li J, Burzynski J N, Lee Y, et al Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients Chest 2004; 126: 1770-1776.
5. Alsultan A, Peloquin C A.Therapeutic drug monitoring in the treatment of tuberculosis: an update Drugs 2014; 74: 839-854.
6. Kimerling M E, Phillips P, Patterson P, Hall M, Robinson C A, Dunlap N E.Low serum antimycobacterial drug levels in nonhiv-infected tuberculosis patients Chest 1998; 113: 1178-1183.
7. Mehta J, Shantaveerapa H, Byrd J R P, Morton S E, Fountain F, Roy T M.Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy Chest 2001; 120: 1520-1524.
8. Heysell S, Moore J L, Keller S J, Houpt E R.Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA Emerg Infect Dis 2010; 16: 1546-1553.
9. Burhan E, Ruesen C, Ruslami R, et al Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients Antimicrob Agents Chemother 2013; 57: 3614-3619.
10. Weiner M, Burman W, Vernon A, et al Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine Am J Respir Crit Care Med 2003; 167: 1341-1347.
11. van Crevel R, Alisjahbana B, de Lange W C M, et al Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia Int J Tuberc Lung Dis 2002; 6: 497-502.
12. Van Tongeren L, Nolan S, Cook V J, FitzGerald JM, Johnston J C.Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis Int J Tuberc Lung Dis 2013; 17: 221-224.
13. Gurumurthy P, Ramachandran G, Kumar A K H, et al Malabsorption of antituberculosis medications by a patient with AIDS N Engl J Med 1992; 327: 1817-1818.
14. Gurumurthy P, Ramachandran G, Kumar A K H, et al Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease Antimicrob Agents Chemother 2004; 48: 4473-4475.
15. Gurumurthy P, Ramachandran G, Kumar A K H, et al Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis Clin Infect Dis 2004; 38: 280-283.
16. Peloquin C A, MacPhee A A, Berning S E.Malabsorption of antimycobacterial medications N Engl J Med 1993; 329: 1122-1123.
17. Peloquin C A, Nitta A T, Burman W J, et al Low antituberculosis drug concentrations in patients with AIDS Ann Pharmacother 1996; 30: 919-925.
18. Sahai J, Gallicano K, Swick L, et al Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection Ann Intern Med 1997; 127: 289-293.
19. Tappero J, Bradford, W Z, Agerton T B, et al Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana Clin Infect Dis 2005; 41: 461-469.
20. Narita M, Hisada M, Thimmappa B, et al Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors Clin Infect Dis 2001; 32: 515-517.
21. McIlleron H, Wash P, Burger A, Norman J, Folb P I, Smith, P.Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients Antimicrob Agents Chemother 2006; 50: 1170-1177.
22. Weiner M, Benator D, Burman W, et al Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis Clin Infect Dis 2005; 40: 1481-1491.
23. Um S, Lee S W, Kwon S Y, et al Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels Int J Tuberc Lung Dis 2007; 11: 972-978.
24. Moher D, Liberati A, Tetzlaff J, Altman D G.Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA Statement Ann Intern Med 2009; 151: 264-269.
25. World Health Organization Global tuberculosis report, 2014 WHO/HTM/TB/2014.08 Geneva, Switzerland: WHO, 2014.
26. Higgins J P, Altman D G, Gøtzsche P C, et al The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 2011; 343: d5928.
27. Wells G, Shea B, O'Connell D, et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-Analyses Ottawa, ON, Canada: Ottawa Hospital Research Institute, 2012.
28. Prins J, Blanker M, Bohnen A, Thomas S, Bosch J.Prevalence of erectile dysfunction: a systematic review of population-based studies Int J Impot Res 2002; 14: 422-432.
29. Ahmed R, Cooper R, Foisy M, Der E, Kunimoto D.Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection J Int Assoc Physicians AIDS Care (Chicago) 2012; 11: 273-276.
30. Babalik A, Ulus I H, Bakirci N, et al Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus Antimicrob Agents Chemother 2013; 57: 5740-5742.
31. Babalk A, Ulus I H, Bakirci N, et al Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients Int J Tuberc Lung Dis 2013; 17: 1442-1447.
32. Fahimi F, Kobarfard F, Tabarsi P, Hemmati S, Salamzadeh J, Baniasadi S.Isoniazid blood levels in patients with pulmonary tuberculosis at a tuberculosis referral center Chemotherapy 2011; 57: 7-11.
33. Fahimi F, Tabarsi P, Kobarfard F, et al Isoniazid, rifampicin and pyrazinamide plasma concentrations and h post dose in patients with pulmonary tuberculosis Int J Tuberc Lung Dis 2013; 17: 1602-1606.
34. Jain N K, Sharma D K, Garg V K, Sharma T N, Mathur R B.Pharmacokinetics of pyrazinamide in patients of pulmonary tuberculosis with jaundice Indian J Tuberc 1991; 38: 221-223.
35. Pea D F, Milaneschi R, Baraldo M, Talmassons G, Furlanut M.Isoniazid and its hydrazine metabolite in patients with tuberculosis Clin Drug Invest 1999; 17: 145-154.
36. Perlman D C, Segal Y, Rosenkranz S, et al The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis Clin Infect Dis 2004; 38: 556-564.
37. Pinheiro V G F, Ramos LMA, Monteiro H S A, et al Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis Braz J Infect Dis 2006; 10: 374-379.
38. Requena-Méndez A, Davies G, Ardrey A, et al Pharmacokinetics of rifampin in peruvian tuberculosis patients with and without comorbid diabetes or HIV Antimicrob Agents Chemother 2012; 56: 2357-2363.
39. Kayhan S, Akgünes-A Therapeutic monitoring of isoniazid, rifampicin, ethambutol and pyrazinamide serum levels in the treatment of active pulmonary tuberculosis and determinants of their serum concentrations Afr J Pharm Pharmacol 2011; 5: 2035-2041.
40. Khantipongse J.Low antitubercular drug levels in newly infected normal hosts Asian Biomed 2013; 7: 407-410.
41. Chideya S, Winston C A, Peloquin C A, et al Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana Clin Infect Dis 2009; 48: 1685-1694.
42. Choudhri S H, Hawken M, Gathua S, et al Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea Clin Infect Dis 1997; 25: 104-111.
43. Cohen K, van Cutsem G, Boulle A, et al Effect of rifampicinbased antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-Associated tuberculosis J Antimicrob Chemother 2008; 61: 389-393.
44. Perlman D C, Segal Y, Rosenkranz S, et al The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis Clin Infect Dis 2005; 41: 1638-1647.
45. Saleri N, Dembélé S M, Villani P, et al Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso J Antimicrob Chemother 2012; 67: 469-472.
46. Shaheen A, Najmi M H, Saeed W, Farooqi Z U R.Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan Scand J Infect Dis 2012; 44: 459-464.
47. Ray J, Gardiner I, Marriott D.Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid Intern Med J 2003; 33: 229-234.
48. Heysell S K, Moore J L, Staley D, Dodge D, Houpt E R.Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA Tuberc Res Treat 2013; 2013.
49. Holland D P, Hamilton C D, Weintrob A C, et al Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection Pharmacotherapy 2009; 29: 503-510.
50. Ruslami R, Nijland H M J, Adhiarta I G N, et al Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type diabetes Antimicrob Agents Chemother 2010; 54: 1068-1074.
51. Chang K C, Leung C C, YewWW, et al Peak plasma rifampicin level in tuberculosis patients with slow culture conversion Eur J Clin Microbiol Infect Dis 2008; 27: 467-472.
52. Facanha M C, Gondim A M B, Pinheiro V G F, et al Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis Braz J Infect Dis 2009; 13: 210-217.
53. Nijland H M J, Ruslami R, Stalenhoef J E, et al Exposure to rifampicin is strongly reduced in patients with tuberculosis and type diabetes Clin Infect Dis 2006; 43: 848-854.
54. Taylor B, Smith P J.Does AIDS impair the absorption of antituberculosis agents? Int J Tuberc Lung Dis 1998; 2: 670-674.
55. Babalik A, Mannix S, Francis D, Menzies D.Therapeutic drug monitoring in the treatment of active tuberculosis Can Respir J 2011; 18: 225-229.
56. McIlleron H, Rustomjee R, Vahedi M, et al Reduced Antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines Antimicrob Agents Chemother 2012; 56: 3232-3238.
57. Ruslami R, NijlandHMJ, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse R E.Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients Antimicrob Agents Chemother 2007; 51: 2546-2751.
58. Ruslami R, Ganiem A R, Dian S, et al Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase trial Lancet Infect Dis 2013; 13: 27-35.
59. Ribera E, Azuaje C, Lopez R M, et al Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIVinfected patients with tuberculosis J Antimicrob Chemother 2007; 59: 690-697.
60. Singhal K C, Varshney M K.Effect of simultaneous isoniazid administration on pharmacokinetic parameters of pyrazinamide J Indian Med Assoc 1991; 89: 227-229.
61. Pasipanodya J G, Gumbo T.A meta-Analysis of selfadministered versus directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients Clin Infect Dis 2013; 57: 21-31.